SecBot SecBot

IMTX drug pipeline

Immatics N.V. · 3 rated drugs
$6.17
−3.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.

IMA203 anzutresgene autoleucel Updated Oct 25

What to watch

The binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.

Bull case
  • Phase 1b data showed compelling efficacy: 56% confirmed ORR, 14.6-month mDOR, 16.2-month mOS in heavily pretreated metastatic melanoma at ASCO 2026, well above standard-of-care benchmarks in later-line melanoma (source: investors.immatics.com press release June 1, 2026)
  • FDA granted RMAT designation (all Breakthrough Therapy benefits) and Orphan Drug designation for both cutaneous and uveal melanoma, providing regulatory acceleration and market exclusivity (source: germanupdate.com, investors.immatics.com)
  • Strong analyst support: 15 of 16 analysts rate Buy/Strong Buy, mean price target ~$17.26 vs. $7.31 current price (~136% implied upside), with Stifel initiating at Buy as recently as Oct 14, 2026
Bear case
  • SUPRAME trial was already amended once because PFS events accrued slower than modeled, dropping the interim analysis raises uncertainty about effect size and could signal a smaller-than-hoped treatment benefit (source: peptideandprotein.com, biotechdistilled.substack.com)
  • A competitor, Iovance's lifileucel (Amtagvi), is already FDA-approved for post-PD-1 melanoma since Feb 2024, and TIL therapy is one of the investigator's choice arms in SUPRAME, setting a high efficacy bar (source: FDA.gov, clinicaltrials.gov)
  • As a single-dose autologous cell therapy, manufacturing complexity, vein-to-vein time, and cost could limit commercial adoption vs. off-the-shelf alternatives (source: Nature Medicine paper on IMA203)
● neutral
Impact
PhasePhase 1
Time to marketSeveral years away, if successful. The drug is still in Phase 1 dose expansion with no registrational trial started.

IMA203CD8 Updated Nov 11

What to watch

Watch for further Phase 1 dose-expansion data updates from Immatics' PRAME franchise at upcoming medical conferences. The more immediate binary catalyst for Immatics is the SUPRAME Phase 3 topline readout for anzu-cel (IMA203) in H1 2027, which is a separate, more advanced asset. IMA203CD8 remains an early-stage pipeline program.

Bull case
  • 51% objective response rate in 98 heavily pretreated patients across multiple solid tumor types is encouraging for an early Phase 1 cell therapy.
  • Second-generation design with enhanced pharmacology may offer improved potency over first-generation TCR-T approaches.
  • PRAME is a validated target expressed in over 50 cancer types, giving broad potential addressable market.
Bear case
  • Still very early-stage (Phase 1); cell therapies for solid tumors have historically struggled with efficacy and durability compared to blood cancers.
  • No registrational trial design or regulatory filing timeline has been announced, meaning commercialization is likely years away.
  • Immatics is burning cash (Q3 2026 net loss of ~$87.5M) and will need additional financing to fund its pipeline.
● neutral
Impact
PhasePhase 1b
Time to marketAt least 3-5 years away from potential approval, assuming successful completion of Phase 1b dose expansion, a registrational Phase 2/3 trial, and FDA review. No registrational trial has been initiated yet.

IMA402 Updated Nov 11

What to watch

The next catalyst for IMA402 is continued data maturation from the ongoing Phase 1b dose expansion cohorts, but no specific readout date has been announced. The company's next major binary event is the SUPRAME Phase 3 topline data for anzu-cel (a different asset) expected in H1 2027. IMA402 data will likely be updated at major medical conferences in 2027.

Bull case
  • Updated Phase 1b data at ESMO 2026 showed a 32% confirmed objective response rate and 91% 1-year overall survival in advanced melanoma patients with high PRAME expression, a compelling signal in heavily pretreated patients.
  • PRAME is expressed in over 50 cancer types, giving IMA402 a broad potential addressable market across multiple solid tumor indications.
  • The favorable safety profile and ability to combine with checkpoint inhibitors opens a clear development path for both monotherapy and combination regimens.
Bear case
  • Still early-stage (Phase 1b) with no registrational trial design announced, meaning approval is years away at best.
  • Competition in TCR bispecifics is intensifying, with Immunocore's approved KIMMTRAK (tebentafusp) and other developers pursuing similar T-cell engager platforms.
  • Immatics reported a Q3 2026 net loss of $87.5M and revenue of only $8M, burning cash while advancing multiple early-stage programs.